<DOC>
	<DOCNO>NCT02170363</DOCNO>
	<brief_summary>The purpose clinical investigation evaluate performance safety HeartMate 3 Left Ventricular Assist System ( HM3 LVAS ) To support obtain CE Mark HM3 LVAS Europe , multi-center clinical study conduct multiple country . The clinical study conduct compliance Declaration Helsinki , ICH/GCP EN ISO 14155:2011 Requirements Clinical Investigations accordance country-specific requirement , one clinical study protocol . This study evaluate performance HM3 LVAS , side effect undesirable condition within acceptable risk weigh intend performance HM3 LVAS accordance Essential Requirements 2 , 5 16 Active Implantable Medical Device Directive 90/385/EEC ( AIMDD ) .</brief_summary>
	<brief_title>HeartMate 3™ CE Mark Clinical Investigation Plan</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Patient legal representative sign Informed Consent Form ( ICF ) 2 . Age ≥ 18 year 3 . BSA ≥ 1.2 m2 4 . NYHA IIIB IV OR ACC/AHA Stage D 5 . LVEF ≤ 25 % 6 . CI ≤ 2.2 L/min/m2 , inotropes 7 . Patients must also meet one follow : On Optimal Medical Management ( OMM ) , base current heart failure practice guideline least 45 last 60 day fail respond , OR In NYHA class IIIB IV heart failure least 14 day AND dependent intraaortic balloon pump ( IABP ) least 7 day , OR Inotrope dependent/unable wean inotropes OR Listed Transplant 8 . Females child bear age must agree use adequate contraception 1 . Etiology HF due associate uncorrected thyroid disease , obstructive cardiomyopathy , pericardial disease , amyloidosis restrictive cardiomyopathy 2 . Technical obstacle pose inordinately high surgical risk , judgment investigator 3 . Existence ongoing mechanical circulatory support ( MCS ) IABP 4 . Positive pregnancy test childbearing potential 5 . Lactating mother 6 . Presence mechanical aortic cardiac valve convert bioprosthesis time LVAD implant 7 . History organ transplant 8 . Platelet count &lt; 100,000 x 103/L ( &lt; 100,000/ml ) 9 . Psychiatric disease/disorder , irreversible cognitive dysfunction psychosocial issue likely impair compliance study protocol LVAS management 10 . History confirm , untreated AAA &gt; 5 cm diameter 11 . Presence active , uncontrolled infection 12 . Intolerance anticoagulant antiplatelet therapy peri/postoperative therapy investigator require base upon patient ' health status 13 . Presence one follow risk factor indication severe end organ dysfunction failure : 1 . An INR ≥ 2.5 due anticoagulation therapy 2 . Total bilirubin &gt; 43 umol/L ( 2.5 mg/dl ) , shock liver , biopsy proven liver cirrhosis 3 . History severe chronic obstructive pulmonary disease ( COPD ) define FEV1/FVC &lt; 0.7 , FEV1 &lt; 50 % predict 4 . Fixed pulmonary hypertension recent PVR ≥ 8 Wood unit unresponsive pharmacologic intervention 5 . History stroke within 90 day prior enrollment , history cerebrovascular disease significant ( &gt; 80 % ) carotid artery stenosis 6 . Serum creatinine ≥221umol/L ( 2.5 mg/dl ) need chronic renal replacement therapy 7 . Significant peripheral vascular disease ( PVD ) accompany rest pain extremity ulceration 14 . Patient moderate severe aortic insufficiency without plan correction pump implant 15 . Pre albumin &lt; 150 mg/L , Albumin &lt; 30g/L ( 3 g/dL ) 16 . Planned BiVAD support prior enrollment 17 . Patient known hypo hyper coagulable state disseminate intravascular coagulation heparin induce thrombocytopenia 18 . Participation clinical investigation likely confound study result affect study 19 . Any condition HF could limit survival less 24 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Ventricular Dysfunction</keyword>
	<keyword>Cardiomyopathies</keyword>
	<keyword>Heart Disease</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Heart-assist device</keyword>
</DOC>